Paul Hockings, Senior Scientific Advisor at Antaros Medical, will speak at the 5th Annual Rare & Genetic Kidney Disease Summit in Boston. He will explore how advanced imaging techniques—particularly Magnetic Resonance Imaging (MRI)—can enhance drug development for rare and genetic kidney diseases. Paul will highlight how imaging can provide deeper insights beyond traditional endpoints like glomerular filtration rate (GFR) and proteinuria, offering new opportunities to support and accelerate therapeutic innovation.
More specifically, his talk will cover the following:
- The Power and Potential of Imaging in Kidney Disease Trials: Discover how advanced imaging can reveal subtle disease progression, measure treatment effects earlier than traditional endpoints, and deliver whole‑organ insights that complement biomarkers such as eGFR and proteinuria
- Current usage of kidney imaging in clinical trials: See how imaging is already shaping trials in ADPKD, CKD, and DKD by enabling precise, reproducible measurements of kidney volume, perfusion, and other structural and functional parameters across global sites
- Expanding Horizons: From Rare Kidney Diseases to Multi‑Organ Insights: Explore the potential of imaging endpoints in rare and genetic kidney diseases, and how integrating kidney imaging with assessments of metabolically linked organs like the heart and liver supports more holistic drug development strategies
Join us for Paul’s presentation at the Rare & Genetic Kidney Disease Summit on Tuesday 30 September @ 3.15 pm EDT. The Rare & Genetic Kidney Disease Drug Development Summit takes place from 29 September – 1 October in Boston, MA.